Relievant gets FDA OK for expanded back-pain-device trial

06/4/2013 | MassDevice.com (Boston)

The FDA has granted Relievant Medsystems investigational device exemption to conduct a larger clinical study of its Intracept basivertebral nerve ablation device. The 200-participant trial will be expanded to include 20 U.S. clinical sites, where the device will be tested for treating recurrent low back pain.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID